The Importance of a New Cardiovascular Risk Factor – Asymmetric Dimethylarginine

Abstract

In the past years, scientific research has highlighted the presence of a new cardiovascular risk factor, the implications of which have not been sufficiently studied so far. It is different from conventional risk factors because it acts independently at the endothelial level, having important proatherogenic properties. Through its action, this risk factor leads to increased oxidative stress and promotes the onset of atherosclerosis faster than other well-known risk factors so far. Asymmetric dimethylarginine (ADMA) is a methylprotein that arises from posttranslational methylation of proteins. Its importance has emerged in recent years, when the rate of cardiovascular mortality among patients with chronic kidney disease has been high. The distinctive element of this risk factor compared to other well-known ones is given by its ability to compete directly with nitric oxide synthase, being its strongest endogenous inhibitor, with strong proatherogenic attributions. Given that ADMA has tight correlations with atherogenesis and endothelial damage, its assessment should be taken into consideration for any patient who has been recently diagnosed with high blood pressure.